U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Safety-related Labeling Changes

Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

ADDYI (NDA-022526)

(FLIBANSERIN)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

12/13/2025 (SUPPL-13)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.3 Central Nervous System Depression

Additions and/or revisions underlined:

ADDYI can cause CNS depression (e.g., somnolence, sedation). In five 24-week, randomized,

placebo-controlled, double-blind trials of premenopausal women with HSDD, the incidence of somnolence, sedation or fatigue was 21% and 8% in patients treated with 100 mg ADDYI once daily at bedtime and placebo, respectively [see Adverse Reactions (6.1) and Clinical Studies (14.1)]. In two similarly designed trials in naturally postmenopausal women with acquired, generalized HSDD, the incidence of somnolence, sedation or fatigue was 10% and 6% in patients less than 65 years of age treated with 100 mg ADDYI once daily at bedtime and placebo, respectively. The risk of CNS depression is increased if ADDYI is taken during waking hours, or if ADDYI is taken with alcohol or other CNS depressants, or with medications that increase flibanserin concentrations, such as CYP3A4 inhibitors [see Contraindications (4), Warnings and Precautions (5.1, 5.2), Adverse Reactions (6.1), and Drug Interactions (7)].

Patients should avoid activities requiring full alertness (e.g., driving or operating machinery) until at least 6 hours after taking ADDYI and until they know how ADDYI affects them [see Clinical Studies (14.3)].

5.4 Hypotension and Syncope with ADDYI Alone

Additions and/or revisions underlined:

The use of ADDYI ? without other concomitant medications known to cause hypotension or syncope ? can cause hypotension and syncope. In five 24-week, randomized, placebo-controlled, double-blind trials of premenopausal women with HSDD, hypotension was reported in 0.2% and <0.1% of ADDYI-treated patients and placebo-treated patients, respectively; syncope was reported in 0.4% and 0.2% of

ADDYI-treated patients and placebo-treated patients, respectively. In two similarly designed trials in naturally postmenopausal women with acquired, generalized HSDD, there was no difference in the incidence of hypotension between ADDYI-treated patients and placebo-treated patients. One case of syncope was reported in the ADDYI treatment group.

6 Adverse Reactions

6.1 Clinical Trials Experience

Extensive changes; please refer to label for complete information

6.2 Postmarketing Experience

Additions and/or revisions underlined:

The following adverse reactions have been identified during post-approval use of ADDYI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

        • Immune system disorders: hypersensitivity reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticaria.

        • Gastrointestinal disorders: vomiting

        • General disorders and administration site conditions: asthenia, feeling abnormal, feeling drunk, malaise

        • Nervous system disorders: headache, presyncope, gait disturbance, vision blurred

        • Psychiatric disorders: brain fog

8 Use in Specific Populations

8.1 Pregnancy

Additions and/or revisions underlined:

Risk Summary

There are no studies of ADDYI in pregnant women to inform whether there is a drug-associated risk in humans. In animals, fetal toxicity only occurred in the presence of significant maternal toxicity including reductions in weight gain and sedation. In pregnant rats and rabbits, adverse reproductive and developmental effects consisted of decreased fetal weight, structural anomalies and increases in fetal loss at exposures greater than 15 times exposures achieved with the recommended human dosage [see Data]. Animal studies cannot rule out the potential for fetal harm.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.5 Geriatric Use

Additions and/or revisions underlined:

ADDYI is not indicated for the treatment of HSDD in geriatric patients [see Warnings and Precautions (5.1. 5.2, and 5.4)]. Safety and effectiveness of ADDYI for the treatment of HSDD have not been established in geriatric patients.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

MEDICATION GUIDE

Additions and/or revisions underlined:

To lower your risk of low blood pressure and fainting (loss of consciousness):

  • Do not drink alcohol close to the time you take your ADDYI dose.

  • After taking ADDYI at bedtime do not drink alcohol until the following day.

    Examples of 1 standard alcoholic drink include:

    • one 12-ounce regular beer

    • 5 ounces of wine

    • 1.5 ounces of distilled spirits or shot

  • Tell your doctor about other medicines you take. Do not take or start taking any prescription or over-the-counter medicines, or herbal supplements without first talking to your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI.

    What is ADDYI?

    ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women <65 years of age who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to:

  • a medical or mental health problem

  • problems in the relationship

  • medicine or other drug use ADDYI is not for use in men.

    ADDYI is not for use to improve sexual performance. ADDYI is not for use in children.

09/29/2021 (SUPPL-10)

Approved Drug Label (PDF)

4 Contraindications

Additions and/or revisions underlined:

ADDYI is contraindicated in patients:

  • Using concomitant moderate or strong CYP3A4 inhibitors [see Boxed Warning and Warnings and Precautions (5.2)].

  • With hepatic impairment [see Boxed Warning and Warnings and Precautions (5.5)].

  • With known hypersensitivity to ADDYI or any of its components. Reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticaria have been reported [see Adverse Reactions (6.2)].

5 Warnings and Precautions

Newly added subsection:

5.6 Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticaria have been reported with ADDYI. ADDYI is contraindicated in women with known hypersensitivity to ADDYI or any of its components [see Adverse Reactions (6.2)].

Immediately discontinue ADDYI and initiate appropriate treatment if a hypersensitivity reaction occurs.

6 Adverse Reactions

Newly added subsection:

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval of ADDYI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune system disorders: hypersensitivity reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticarial.

10/09/2019 (SUPPL-8)

Approved Drug Label (PDF)

Boxed Warning

Interaction with Alcohol

Additions and/or revisions underlined:

The use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope. Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening.

5 Warnings and Precautions

Additions and/or revisions underlined:

5.1 Hypotension and Syncope due to an Interaction with Alcohol

Taking ADDYI within two hours after consuming alcohol increases the risk of severe hypotension and syncope. To reduce this risk, counsel patients to wait at least two hours after drinking one or two standard alcoholic drinks before taking ADDYI at bedtime.

Patients who drink three or more standard alcoholic drinks should skip their ADDYI dose that evening. One standard alcoholic drink contains 14 grams of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).

After taking ADDYI at bedtime, advise patients to not use alcohol until the following day.

6 Adverse Reactions

6.1 Clinical Trials Experience

Hypotension, Syncope, and CNS Depression in Studies of Healthy Subjects

Hypotension, Syncope, and CNS Depression with Alcohol

Alcohol and ADDYI Administration at the Same Time

Additions and/or revisions underlined:

The first alcohol interaction study was conducted in 25 healthy subjects (23 men and 2 premenopausal women). The study excluded subjects who drank fewer than five alcoholic drinks per week and those with a history of orthostatic hypotension, or syncope. A single dose of 100 mg ADDYI was administered concurrently with 0.4 g/kg or 0.8 g/kg alcohol in the morning; alcohol was consumed over 10 minutes.

Hypotension or syncope requiring therapeutic intervention (ammonia salts and/or placement in supine or Trendelenburg position) occurred in 4 (17%) of the 23 subjects co-administered 100 mg ADDYI and 0.4 g/kg alcohol (equivalent to two 12-ounce cans of beer containing 5% alcohol content, two 5-ounce glasses of wine containing 12% alcohol content, or two 1.5-ounce shots of 80-proof spirit in a 70 kg person). In these four subjects, all of whom were men, the magnitude of the systolic blood pressure reductions ranged from 28 to 54 mmHg and the magnitude of the diastolic blood pressure reductions ranged from 24 to 46 mmHg. In addition, 6 (25%) of the 24 subjects co-administered 100 mg ADDYI and 0.8 g/kg alcohol (equivalent to four 12-ounce cans of beer containing 5% alcohol content, four 5-ounce glasses of wine containing 12% alcohol content, or four 1.5-ounce shots of 80-proof spirit in a 70 kg person) experienced orthostatic hypotension when standing from a sitting position. The magnitude of the systolic blood pressure reduction in these 6 subjects ranged from 22 to 48 mmHg, and the diastolic blood pressure reductions ranged from 0 to 27 mmHg. One of these subjects required therapeutic intervention (ammonia salts and placement supine with the foot of the bed elevated). There were no events requiring therapeutic interventions when ADDYI or alcohol were administered alone.

In this study, somnolence was reported in 67%, 74%, and 92% of subjects who received ADDYI alone, ADDYI in combination with 0.4 g/kg alcohol, and ADDYI in combination with 0.8 g/kg alcohol, respectively.

In the second alcohol interaction study, 96 healthy premenopausal women received a single dose of 100 mg ADDYI concurrently with 0.2 g/kg, 0.4 g/kg, or 0.6 g/kg alcohol (equivalent to one, two or three alcoholic drinks in a 70 kg person, respectively) in the morning. The study excluded subjects with a history of syncope, orthostatic hypotension, hypotensive events, and dizziness, and those with a resting systolic blood pressure less than 110 mmHg or diastolic blood pressure less than 60 mmHg.

In this study, no subjects experienced syncope or hypotension requiring therapeutic intervention. However, subjects who were already hypotensive (blood pressure below 90/60 mmHg) or symptomatic (e.g., dizzy) while in the semi-recumbent position were not permitted to stand for orthostatic measurements, and those with blood pressures below 90/40 mmHg while in the semi-recumbent position had blood pressures repeated until it was deemed safe for them to change position. More subjects had missing or delayed orthostatic measurements (in general, due to hypotension or dizziness) when receiving ADDYI and alcohol, compared to those who received alcohol alone or ADDYI alone. This pattern of missing or delayed orthostatic measurements is concerning for a risk of hypotension and syncope if those subjects had been allowed to stand.

In this study, somnolence was reported in 81-89% of subjects administered ADDYI with alcohol, compared to 25-41% of subjects administered alcohol alone and 84% of subjects taking ADDYI alone. Dizziness was reported in 27-40% of subjects administered ADDYI with alcohol, compared to 6-20% of subjects administered alcohol alone and 31% of subjects taking ADDYI alone.

Alcohol Use at Various Time Intervals Before ADDYI Administration

In a third alcohol interaction study, 64 healthy premenopausal women consumed 0.4 g/kg alcohol (equivalent to 2 alcoholic drinks in a 70 kg person) two, four or six hours prior to receiving ADDYI 100 mg or placebo in the afternoon. The study excluded subjects with a history or presence of orthostatic hypotension, history of

hypotension, syncope, or dizziness. Prior to receiving alcohol, the subjects in the ADDYI arm had taken ADDYI for three days to achieve steady state. Syncope occurred in one subject who received alcohol alone. The incidences of orthostatic hypotension and hypotension (blood pressure below 90/60 mmHg) at all time points were similar among subjects administered alcohol before ADDYI, subjects administered alcohol alone, and subjects administered ADDYI alone. Three subjects were unable to stand due to feeling dizzy or hypotension; two following alcohol and ADDYI separated by 2 and 6 hours, and one subject who received ADDYI alone.

In this study, somnolence was reported in 35-53% of subjects administered ADDYI and alcohol, compared to 5-8% of subjects taking alcohol alone and 50% of subjects taking ADDYI alone. Dizziness was reported in 5-13% of subjects administered ADDYI and alcohol, compared to 0-3% of subjects taking alcohol alone and 12% of subjects taking ADDYI alone.

Alcohol Use in the Evening Before Bedtime ADDYI Administration

In another alcohol interaction study, 24 premenopausal women consumed 0.4 g/kg alcohol (equivalent to 2 alcoholic drinks in a 70 kg person) during the evening meal two and a half to four hours prior to taking ADDYI 100 mg at bedtime. There were no cases of syncope. Upon rising the following morning, the incidence of hypotension was 23% among subjects administered ADDYI after alcohol, 23% among subjects administered alcohol alone and 36% with ADDYI alone. No cases of somnolence or dizziness were reported in this study. Conclusions are limited because blood pressure and orthostatic measurements were not taken after ADDYI administration until the following morning.

7 Drug Interactions

Table 3: Clinically Significant Drug Interactions with ADDYI

Additions and/or revisions underlined to this subsection of table:

Alcohol

Preventing or Managing DI: Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more alcoholic drinks that evening.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT COUNSELING INFORMATION

Hypotension and Syncope

Additions and/or revisions underlined:

Inform patients that ADDYI can cause severe hypotension and syncope, particularly when taken close in time with alcoholic drinks or with moderate or strong CYP3A4 inhibitors.

  • Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed 3 or more standard alcoholic drinks that evening.

  • After taking ADDYI at bedtime, advise patients to not use alcohol until the following day.

  • Advise patients that moderate or strong CYP3A4 inhibitors are contraindicated with ADDYI and ask patients to report the use of a new prescription or non-prescription medication or other products that contain CYP3A4 inhibitors (e.g., grapefruit juice, St. John’s Wort).

10/09/2019 (SUPPL-9)

Approved Drug Label (PDF)

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

MEDICATION GUIDE

Newly created document to conform to new REMS requirement as related to alcohol:

What is the most important information I should know about ADDYI?

Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take ADDYI and:

  • drink alcohol close to the time you take your ADDYI dose.

  • Wait at least 2 hours after drinking 1 or 2 standard alcoholic drinks before taking ADDYI at bedtime.

  • Examples of 1 standard alcoholic drink include:

    • one 12-ounce regular beer

    • 5 ounces of wine

    • 1.5 ounces of distilled spirits or shot

  • If you drink 3 or more standard alcoholic drinks in the evening, skip your ADDYI dose at bedtime.

  • After you have taken your ADDYI at bedtime do not drink alcohol until the following day.

What should I avoid while taking ADDYI?

If you drink alcohol, see “What is the most important information I should know about ADDYI?”